Table 1.
Changes in clinical and metabolic parameters pre- and post-nephrectomy in the study cohort (N=9).
| Variable | Pre-nephrectomy, Median (Min, Max) | Post-nephrectomy Median (Min, Max) | Delta (Post-Pre), Median (Min, Max) | P value * |
|---|---|---|---|---|
| Weight (kg) | 85.8 (53.9, 110.5) | 87 (53.2, 116.8) | 0 (−2.3, 6.35) | 0.48 |
| BMI (kg/m2) | 29 (21.5, 36.7) | 30.5 (21.2, 38.1) | 0.04 (−2.70, 2.08) | 0.48 |
| Subcutaneous fat area (cm2), median (min, max)¶ | 234.2 (44.4, 358.6) | Not measured | ||
| Visceral fat area (cm2), median (min, max)¶ | 105.9 (24.4, 191.8) | Not measured | ||
| Visceral fat /Total fat area ratio (min, max)¶ | 0.31 (0.14, 0.41) | Not measured | ||
| SBP (mmHg) | 112 (100, 128) | 115 (109, 120) | 3 (−8, 8) | 0.59 |
| DBP (mmHg) | 62 (60, 80) | 72 (66, 81) | 6 (2, 12) | 0.04 |
| HbA1C (%) | 5.4 (4.7, 6) | 5.4 (4.6, 5.9) | 0 (−0.2, 0.3) | 0.72 |
| Fasting glucose (mg/dL) | 95 (75, 105) | 93 (74, 105) | −3 (−6, 13) | 0.51 |
| Fasting insulin (mU/mL) | 8.4 (5, 19.7) | 11.4 (6.4, 25) | 3.4 (−1.4, 15.3) | 0.02 |
| Fasting c-peptide (ng/mL) | 2 (1.3, 3.1) | 2.7 (1.8, 4.9) | 0.6 (0.1, 1.2) | 0.01 |
| Glucose 2hr (mg/dL) | 119 (72, 135) | 92 (82, 117) | −21 (−43, 19) | 0.05 |
| Glucose AUC (hr*mg/dL) | 228.9 (152.4, 247.5) | 209.3 (178.8, 262.8) | 3.2 (−49.1, 139) | 0.77 |
| Insulin AUC (hr*mU/mL) | 60.7 (34.8, 134.8) | 101.7 (23.8, 189) | 33.3 (−16, 107.7) | 0.04 |
| C-peptide AUC (hr*ng/mL) | 9.3 (5.8, 13.6) | 14.5 (10.3, 19.3) | 5.2 (1.5, 9.9) | 0.02 |
| TG (mg/dL) | 102 (36,190) | 115 (43, 231) | 21 (−54, 49) | 0.17 |
| HDL-C (mg/dL) | 51 (42, 72) | 48 (43,84) | −2 (−12, 12) | 0.64 |
| TG/HDL-C | 1.73 (0.50, 3.57) | 2.55 (0.51, 5.37) | 0.65 (−1.0, 1.8) | 0.21 |
| eGFR (mL/min/1.73 m2) | 108 (77.6, 120) | 76.5 (58, 94) | −38.5 (−47.9, −28) | 0.01 |
| Adipokines | ||||
| Adiponectin (ng/mL) | 8800 (6100, 16250) | 8150 (5400, 18400) | 700 (−1400, 4450) | 0.68 |
| Leptin (ng/mL) | 19.5 (6.2, 64.7) | 28.2 (5.4, 86.7) | 8.6 (−16.7, 26.8) | 0.17 |
| Insulin sensitivity surrogate index from fasting sample | ||||
| HOMA-IR** | 2.0 (0.96, 4.9) | 2.9 (1.2, 5.9) | 0.8 (−0.3, 3.9) | 0.03 |
| Insulin sensitivity surrogate indices derived from MMTT | ||||
| AUC insulin/glucose (pmol/mmol) | 30.9 (20.6, 75.6) | 62.1 (15.4, 119.3) | 17.5 (−5.1, 61.5) | 0.01 |
| Matsuda ISI*** | 5.9 (2.5, 13.6) | 3.9 (2.0, 11) | −2 (−4, 2.9) | 0.05 |
Abbreviations: BMI= body mass index; SBP=systolic blood pressure; DBP=diastolic blood pressure; AUC= are under curve; TG=triglyceride; HDL-C= high density lipoprotein cholesterol; eGFR=estimated glomerular filtration rate; HOMA-IR= Homeostatic model assessment for insulin resistance; MMTT= mix meal tolerance test; Matsuda ISI= Matsuda insulin sensitivity index; OGIS=oral glucose insulin sensitivity index.
Wilcoxon signed-rank test.
HOMA-IR >2.5 shows liver insulin resistance.
Matsuda ISI <2.5 shows whole body insulin resistance, mainly peripheral insulin resistance at the skeletal muscle and adipose tissue level.
Visceral and subcutaneous fat area were measurement by a single CT axial image at L3 vertebral level, pre-nephrectomy period.